Immunophage closes near-RMB100m Pre A

Immunophage has recently completed a Pre-A round of financing of nearly 100 million yuan, led by Jinfang Hongrui Capital, with participation from five institutions including Ennovation Venture Capital and Yang Zi Investment Group. The proceeds will be mainly used to promote the company’s two core product lines for IND clinical declaration and early development of more than two new drug projects.

Immunophage has recently completed a Pre-A round of financing of nearly 100 million yuan, led by Jinfang Hongrui Capital, with participation from five institutions including Ennovation Venture Capital and Yang Zi Investment Group. The proceeds will be mainly used to promote the company’s two core product lines for IND clinical declaration and early development of more than two new drug projects.

Established in 2016, Immunophage is a developer of cancer, autoimmune disease and neurodegenerative disease therapeutics. The company’s cancer therapies aim to inhibit tumor growth and Myeloid-derived suppressor cell production, while the company’s other therapies also aim to provide multi-faceted treatment, enabling healthcare professionals to prescribe more effective treatments to their patients.

In addition to the fast-moving small molecule R&D projects, Immunophage also has corresponding productportfolio for monoclonal antibodies and dual-anti-cancer drugs, and they are all category-1 new drugs independently developed by the company. On the indications’ side, the company also has corresponding reserve product portfolio for multiple myeloma, solid tumors, and peripheral neuralgia after chemotherapy. The company will advance these projects in an orderly fashion.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/08/immunophage-closes-near-rmb100m-pre-a/.

Leave a Reply

Please Login to Comment